<DOC>
	<DOCNO>NCT02154139</DOCNO>
	<brief_summary>The purpose survey examine safety efficacy long-term use ( 96 week ) leuprorelin acetate SR ( slow release ) 11.25 milligram ( mg ) injection ( Leuplin SR 11.25 mg Injection ) premenopausal breast cancer patient daily medical practice , well examine factor influence safety efficacy treatment leuprorelin acetate SR 11.25 mg injection ( Leuplin SR 11.25 mg Injection ) .</brief_summary>
	<brief_title>Leuprorelin Acetate SR 11.25 mg Injection Specified Drug-use Survey `` Long-term Use Survey Premenopausal Breast Cancer Patients ( 96 Weeks ) ''</brief_title>
	<detailed_description>This survey design examine safety efficacy long-term use ( 96 week ) leuprorelin acetate 3 month depot injection ( Leuplin SR 11.25 mg Injection ) premenopausal breast cancer patient daily medical practice , well examine factor influence safety efficacy treatment leuprorelin acetate SR 11.25 mg injection ( Leuplin SR 11.25 mg Injection ) . For adult , 11.25 mg leuprorelin acetate usually administer subcutaneously every 12 week . Prior injection , plunger rod syringe push upward needle point upward , allow entire suspension fluid contain transferred powder . The powder fully suspend fluid ensure bubble generate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Premenopausal breast cancer patient ( patient advance recurrent breast cancer patient receive adjuvant therapy ) . Patients history treatment Leuplin SR 11.25 mg Injection</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pharmacological therapy</keyword>
</DOC>